BPC-157, a synthetic peptide marketed for injury recovery and pain relief, is seeing increased use despite a lack of clinical evidence regarding its safety and effectiveness.

BPC-157, a synthetic peptide often called the "Wolverine" peptide, is gaining popularity for injury recovery and pain relief. While proponents claim it promotes tissue healing, medical experts warn that human evidence is limited and its long-term safety profile remains unknown. In July 2026, an FDA advisory panel voted to allow the substance to be eligible for pharmacy compounding, though it remains unapproved by the agency.

Rising Use and Clinical Findings

A September 2026 preprint analyzing over 15 million medical records identified 1,039 individuals using BPC-157, noting a roughly 33-fold increase in new users between 2020 and 2026. The study found that 33% of patients used the peptide for pain relief, while 27% of the cohort reported improvements. However, lead author Venky Soundararajan noted that adverse events are likely underreported in clinical records, and the study has not yet undergone peer review.

Expert Warnings and Regulatory Status

Medical professionals, including sports medicine specialist Dr. Bert Mandelbaum, caution against using BPC-157, citing a lack of efficacy data and potential risks like injection-site infections. The FDA's recent 8-6 vote to add BPC-157 to the Section 503A bulk drug substances list allows for pharmacy compounding but does not constitute federal approval. Experts emphasize that patients should consult with doctors regarding proven alternatives and disclose any use of unapproved peptides.